Demographics and disease characteristics at transplant for unweighted and weighted samples in the 7/8 HLA-MMUD HCT cohort for the abatacept + CNI/MTX vs CNI/MTX comparison
| Characteristic . | Unweighted samples . | Weighted samples . | ||
|---|---|---|---|---|
| Abatacept + CNI/MTX (n = 54)∗ . | CNI/MTX (n = 162) . | Abatacept + CNI/MTX (n = 54)∗ . | CNI/MTX (n = 161) . | |
| Age, y | ||||
| Mean (SD) | 35.9 (22.8) | 47.9 (16.2) | 47.1 (19.2) | 45.9 (17.0) |
| Median (range) | 36.5 (6-76) | 51.0 (10-74) | 51.0 (6-76) | 49.0 (10-74) |
| Age category (y), n (%) | ||||
| ≤21 | 23 (42.6) | 9 (5.6) | 8.6 (15.9) | 12.8 (7.9) |
| >21 | 31 (57.4) | 153 (94.4) | 45.3 (84.1) | 148.7 (92.1) |
| Sex, n (%) | ||||
| Male | 36 (66.7) | 87 (53.7) | 33.4 (62.1) | 95.5 (59.1) |
| Female | 18 (33.3) | 75 (46.3) | 20.4 (37.9) | 66.0 (40.9) |
| Race, n (%) | ||||
| White | 39 (72.2) | 135 (83.3) | 38.8 (72.1) | 133.4 (82.6) |
| Black or African American | 9 (16.7) | 6 (3.7) | 10.9 (20.3) | 6.7 (4.1) |
| Asian | 3 (5.6) | 6 (3.7) | 2.4 (4.5) | 5.4 (3.4) |
| Not reported | 3 (5.6) | 15 (9.3) | 1.7 (3.1) | 16.0 (9.9) |
| Karnofsky/Lansky performance score, n (%)† | ||||
| 70 or 80 | 15 (27.8) | 53 (32.7) | 16.3 (30.3) | 50.9 (31.5) |
| 90 to 100 | 39 (72.2) | 109 (67.3) | 37.5 (69.7) | 110.6 (68.5) |
| Disease, n (%) | ||||
| AML | 20 (37.0) | 81 (50.0) | 24.6 (45.6) | 74.4 (46.1) |
| ALL | 13 (24.1) | 31 (19.1) | 7.9 (14.6) | 29.3 (18.2) |
| MDS or MDS/MPN unclassifiable | 12 (22.2) | 32 (19.8) | 13.2 (24.4) | 34.2 (21.2) |
| CML or CNL | 6 (11.1) | 7 (4.3) | 4.3 (8.1) | 12.8 (8.0) |
| HL + NHL | 3 (5.6) | 11 (6.8) | 3.9 (7.3) | 10.7 (6.6) |
| Disease status, n (%)‡ | ||||
| Early | 33 (61.1) | 84 (51.9) | 38.7 (71.8) | 87.4 (54.1) |
| Intermediate | 13 (24.1) | 28 (17.3) | 8.2 (15.3) | 27.9 (17.3) |
| Advanced | 5 (9.3) | 39 (24.1) | 3.1 (5.7) | 35.6 (22.0) |
| Chemotherapy sensitive | 3 (5.6) | 6 (3.7) | 3.9 (7.3) | 6.5 (4.1) |
| Chemotherapy resistant | 0 | 5 (3.1) | 0 | 4.1 (2.5) |
| Conditioning intensity, n (%) | ||||
| Myeloablative | 41 (75.9) | 107 (66.0) | 38.2 (70.8) | 110.6 (68.5) |
| Reduced intensity or nonmyeloablative | 13 (24.1) | 55 (34.0) | 15.7 (29.2) | 50.9 (31.5) |
| Stem cell source, n (%) | ||||
| Bone marrow | 31 (57.4) | 44 (27.2) | 15.9 (29.5) | 50.2 (31.1) |
| Peripheral blood | 23 (42.6) | 118 (72.8) | 38.0 (70.5) | 111.3 (68.9) |
| CNI type, n (%) | ||||
| Tacrolimus | 33 (61.1) | 153 (94.4) | 46.7 (86.7) | 140.6 (87.1) |
| Cyclosporine | 21 (38.9) | 9 (5.6) | 7.2 (13.3) | 20.8 (12.9) |
| HCT-CI, n (%) | ||||
| 0 | 16 (29.6) | 50 (30.9) | 10.1 (18.8) | 49.4 (30.6) |
| 1 to 2 | 13 (24.1) | 32 (19.8) | 17.5 (32.5) | 33.9 (21.0) |
| ≥3 | 25 (46.3) | 80 (49.4) | 26.3 (48.7) | 78.2 (48.4) |
| Median (range) duration of follow-up, d§ | 1429 (359-2268) | 1470 (190-2839) | 1429 (359-2268) | 1471 (190-2839) |
| Characteristic . | Unweighted samples . | Weighted samples . | ||
|---|---|---|---|---|
| Abatacept + CNI/MTX (n = 54)∗ . | CNI/MTX (n = 162) . | Abatacept + CNI/MTX (n = 54)∗ . | CNI/MTX (n = 161) . | |
| Age, y | ||||
| Mean (SD) | 35.9 (22.8) | 47.9 (16.2) | 47.1 (19.2) | 45.9 (17.0) |
| Median (range) | 36.5 (6-76) | 51.0 (10-74) | 51.0 (6-76) | 49.0 (10-74) |
| Age category (y), n (%) | ||||
| ≤21 | 23 (42.6) | 9 (5.6) | 8.6 (15.9) | 12.8 (7.9) |
| >21 | 31 (57.4) | 153 (94.4) | 45.3 (84.1) | 148.7 (92.1) |
| Sex, n (%) | ||||
| Male | 36 (66.7) | 87 (53.7) | 33.4 (62.1) | 95.5 (59.1) |
| Female | 18 (33.3) | 75 (46.3) | 20.4 (37.9) | 66.0 (40.9) |
| Race, n (%) | ||||
| White | 39 (72.2) | 135 (83.3) | 38.8 (72.1) | 133.4 (82.6) |
| Black or African American | 9 (16.7) | 6 (3.7) | 10.9 (20.3) | 6.7 (4.1) |
| Asian | 3 (5.6) | 6 (3.7) | 2.4 (4.5) | 5.4 (3.4) |
| Not reported | 3 (5.6) | 15 (9.3) | 1.7 (3.1) | 16.0 (9.9) |
| Karnofsky/Lansky performance score, n (%)† | ||||
| 70 or 80 | 15 (27.8) | 53 (32.7) | 16.3 (30.3) | 50.9 (31.5) |
| 90 to 100 | 39 (72.2) | 109 (67.3) | 37.5 (69.7) | 110.6 (68.5) |
| Disease, n (%) | ||||
| AML | 20 (37.0) | 81 (50.0) | 24.6 (45.6) | 74.4 (46.1) |
| ALL | 13 (24.1) | 31 (19.1) | 7.9 (14.6) | 29.3 (18.2) |
| MDS or MDS/MPN unclassifiable | 12 (22.2) | 32 (19.8) | 13.2 (24.4) | 34.2 (21.2) |
| CML or CNL | 6 (11.1) | 7 (4.3) | 4.3 (8.1) | 12.8 (8.0) |
| HL + NHL | 3 (5.6) | 11 (6.8) | 3.9 (7.3) | 10.7 (6.6) |
| Disease status, n (%)‡ | ||||
| Early | 33 (61.1) | 84 (51.9) | 38.7 (71.8) | 87.4 (54.1) |
| Intermediate | 13 (24.1) | 28 (17.3) | 8.2 (15.3) | 27.9 (17.3) |
| Advanced | 5 (9.3) | 39 (24.1) | 3.1 (5.7) | 35.6 (22.0) |
| Chemotherapy sensitive | 3 (5.6) | 6 (3.7) | 3.9 (7.3) | 6.5 (4.1) |
| Chemotherapy resistant | 0 | 5 (3.1) | 0 | 4.1 (2.5) |
| Conditioning intensity, n (%) | ||||
| Myeloablative | 41 (75.9) | 107 (66.0) | 38.2 (70.8) | 110.6 (68.5) |
| Reduced intensity or nonmyeloablative | 13 (24.1) | 55 (34.0) | 15.7 (29.2) | 50.9 (31.5) |
| Stem cell source, n (%) | ||||
| Bone marrow | 31 (57.4) | 44 (27.2) | 15.9 (29.5) | 50.2 (31.1) |
| Peripheral blood | 23 (42.6) | 118 (72.8) | 38.0 (70.5) | 111.3 (68.9) |
| CNI type, n (%) | ||||
| Tacrolimus | 33 (61.1) | 153 (94.4) | 46.7 (86.7) | 140.6 (87.1) |
| Cyclosporine | 21 (38.9) | 9 (5.6) | 7.2 (13.3) | 20.8 (12.9) |
| HCT-CI, n (%) | ||||
| 0 | 16 (29.6) | 50 (30.9) | 10.1 (18.8) | 49.4 (30.6) |
| 1 to 2 | 13 (24.1) | 32 (19.8) | 17.5 (32.5) | 33.9 (21.0) |
| ≥3 | 25 (46.3) | 80 (49.4) | 26.3 (48.7) | 78.2 (48.4) |
| Median (range) duration of follow-up, d§ | 1429 (359-2268) | 1470 (190-2839) | 1429 (359-2268) | 1471 (190-2839) |
Weighted numbers of patients were categorized using stabilized inverse probability of treatment weighing with propensity scores. Propensity scores were obtained from a logistic regression model including sex, disease, age, HCT graft source, conditioning intensity, Karnofsky/Lansky performance score, and CNI type as covariates. Primary end point cohort comprised patients receiving abatacept + CNI/MTX vs CNI/MTX alone.
Adapted from Kean et al.22-25
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CNL, chronic neutrophilic leukemia; HCT-CI, HCT-specific comorbidity index; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; SD, standard deviation.
The abatacept + CNI/MTX group included 42 patients from the ABA2 clinical trial, in addition to 12 patients treated outside of the trial.
Two patients treated with abatacept in the ABA2 trial had reported performance scores of 80%; however, the performance score reported in the CIBMTR database for these patients was 70%. Due to the small number of patients treated with abatacept, these patients were included with performance score based on that reported from the ABA2 trial.
chemotherapy-sensitive/chemotherapy-resistant distinction is specific to patients with lymphoma.
Duration of follow-up was defined as the date of transplant to the date of death or last follow-up. Median was estimated using the reverse Kaplan-Meier method; minimum and maximum values are summarized among patients who were alive at the end of follow-up.